Efficient early identification of primary immunodeficiency disease (PID) is important for prognosis, but is not an easy task for non-immunologists. The Clinical Working Party of the European Society for Immunodeficiencies (ESID) has composed a multi-stage diagnostic protocol that is based on expert opinion, in order to increase the awareness of PID among doctors working in different fields. The protocol starts from the clinical presentation of the patient; immunological skills are not needed for its use. The multi-stage design allows cost-effective screening for PID within the large pool of potential cases in all hospitals in the early phases, while more expensive tests are reserved for definitive classification in collaboration with an immunologist at a later stage. Although many PIDs present in childhood, others may present at any age. The protocols presented here are therefore aimed at both adult physicians and paediatricians. While designed for use throughout Europe, there will be national differences which may make modification of this generic algorithm necessary.
Introduction
Classical primary immunodeficiency disease (PID) [1, 2] is relatively rare (approximately 1 : 500-1 : 500 000 in the general population, with variable degrees of ascertainment in different countries). It has therefore not been easy to generate sufficient evidence to support diagnostic decisions. Although many PIDs present in childhood, the most common clinically significant PID, common variable immunodeficiency (CVID), has a peak onset in the second and third decades of life. Early detection of PID, before serious infections have compromised the patient's general condition, is important for the proband's prognosis, and for timely genetic counselling of his family [2] . Adult physicians as well as paediatricians need therefore to consider PID as a potential diagnosis. However, efficient identification of PID within the large pool of potential cases is difficult for non-immunologists. Previously published protocols for diagnosing PID (e.g. [3, 4] ). are founded on the traditional classification of antibody, T lymphocyte, phagocyte and complement deficiencies. They require at least some knowledge of the immune system and its defects by their users which non-immunologists often lack, making recognition of these conditions difficult [5] .
Based on a Dutch initiative [6] [7] [8] , the Clinical Working Party of the European Society for Immunodeficiencies (ESID) has composed a protocol for diagnosing PID. This protocol is based necessarily on expert opinion; validation will need to be obtained with clinical practice, possibly leading to amendments in the future. The protocol starts from the clinical presentation of the patient. Not only can this be recognized by all doctors, it is also the best reflection of the physiological effect of the underlying disorder [9] . The protocol is aimed at both paediatricians and adult physicians. The multi-stage design allows timely identification of potential PID in all hospitals, with simple screening tests in the initial phases of the protocol. More costly elaborate tests are reserved for definitive classification at a later stage, in collaboration with an immunologist and specialized laboratory.
such as the failure-to-thrive they may cause in children, the constitutional symptoms in adults such as weight loss, or concomitant syndrome-specific symptoms such as hypocalcaemia in DiGeorge syndrome. Autoimmune manifestations [11] can be a presenting feature of PID, especially in adults, as well as unusual lymphoid or granulomatous diseases. A good family history is important for the prompt recognition of genetic disorders, although many mutations may be new and the family history is not necessarily positive [2] .
It is important to remember the possibility of an anatomical defect, especially when infections recur at the same anatomical site. Also, periodic fever may be difficult to distinguish from recurrent infection [12] .
Relevant symptoms and signs from the history and physical examination that should alert any physician to potential PID are listed in Table 1 . Any suspicion of a severe immunodeficiency, such as SCID, should result in the immediate involvement of a clinical immunologist.
Recognizing the different clinical presentations of PID
It is important for all doctors to learn to recognize the different patterns of clinical presentation of PIDs (Table 2 , column 1). General practitioners can use these clinical presentations to select patients for referral. Secondary immunodeficiencies (e.g. HIV infection [13] ) present in a similar fashion, and occur much more frequently than PIDs in some parts of the world, so it is important to be able to eliminate any underlying condition. It is not necessary to understand immunological mechanisms (Table 2 , column 2) to be able to use these different patterns for reliable early suspicion of potential PID.
Other features can be useful to distinguish between the different clinical presentations of PIDs. In children, the time of onset of symptoms can help to elucidate the underlying aetiology. For instance, as long as maternal immunoglobulin is present in the first months of life, antibody deficiency in the child may remain unnoticed [14] . Recurrent bacterial infections will only become prominent later. If only certain pathogens cause clinical problems, as in undue mycobacterial sensitivity, some time is generally needed to encounter these pathogens. However, if ubiquitous opportunistic pathogens cannot be combated, problems will start very early in life. If the immunodeficiency develops later in life, as in common variable immunodeficiency disorder (CVID), the infections will also start later.
The type of pathogen encountered (Table 2 , column 3) is causally related to the underlying immunodeficiency [10] . For instance, extracellular encapsulated bacteria that cause ear, nose and throat (ENT) and airway infections are normally cleared by opsonization with specific antibody and complement, and subsequent elimination by phagocytosis. Fungi and bacteria that are normally present on the skin and mucosal surfaces are kept at bay by local phagocytosis. Cytokines and cytotoxic substances secreted by activated T lymphocytes need to interact with functional macrophages for the elimination of intracellular and slow-growing pathogens. Therefore, specific immunological defects will lead to particular patterns of infection which, together with other special features ( Table 2 , column 4), help to differentiate reliably between the different clinical presentations of PID.
Following the appropriate diagnostic protocol
In column 5 of Table 2 , the user is directed towards the appropriate multi-stage diagnostic protocol for each clinical presentation for the analysis of possible underlying immunodeficiency. These Protocols 1, 2 and 3 (see Figs 1-3 ) in fact represent the traditional division into humoral (Ig + C), cellular and phagocyte deficiencies, respectively.
The Protocols comprise several steps. Severe defects are ruled out first, with widely available screening tests that should be accessible to the whole range of hospital doctors. Less severe forms of PID can be diagnosed later, after more frequent non-immunological diseases ( Table 2 , column 6) have been ruled out. The help of specialized immunology laboratories will be needed for definitive classification using the more elaborate tests presented downstream in the Protocols. Age-related reference values, or controls run in parallel, are needed for correct interpretation of the results.
The advice of an immunologist is extremely important, even during the diagnostic process. In Table 2 , the degree of urgency for performing the various tests is outlined in column 5. Areas in italics in the Protocols demarcate the test phases for which collaboration with an immunologist is highly recommended. Detailed information about the various PIDs can also be found by checking the references to current review articles, which are mentioned in Table 2 (column 2).
Anticipating future developments
In the past two decades, there has been an explosion of knowledge concerning PIDs. This will probably be followed by the identification of many more disease entities in the near future, especially of those with a less overt clinical phenotype [9] . This implies that the multi-stage diagnostic protocol presented here will need to be revised from time to time. It will probably even turn out that PIDs − albeit with varying severity − are more common than we think at present. Failure to thrive from early infancy T-lymphocyte deficiency [19] (remember HIV) [13] . STAT1 deficiency [20] . Hypermorphic mutations in I [19] (remember HIV) [13] . WAS [19] .
STAT1 deficiency [20] . Hypermorphic mutations in I Intracellular bacteria: T lymphocyte-macrophage interaction for cytokine production; auto-antibodies to γ -interferon [20] . Meningococci: complement deficiency [15] , sometimes antibody deficiency [14, 16] . Candida: T-lymphocyte deficiency [19] , CMC [22] . Encapsulated bacteria: antibody deficiencies [14, 16] . Pneumococci: IRAK4 deficiency [21] . No/ delayed fever/raise in CRP: deficiency in NF κ B signalling (IRAK4, NEMO, I κ B α deficiency) [21] . Encapsulated bacterial sepsis: asplenia [23] . Excessive warts: epidermodysplasia verruciformis, WHIM. Herpesviruses: NK-cell deficiency. X-linked lymphoproliferative syndrome [25] Normally no other recurrent infectious problems 
Protocol 1
Step 1 Rule out severe antibody deficiency and neutropenia.
Perform
Blood count and differential (platelet volume, absolute lymphocyte count, neutrophil and eosinophil counts), IgG, IgA, and IgM
Next step Neutropenia: go to Protocol 3, step 2. Agammaglobulinaemia: go to step 3. Decreased level of at least one isotype: go to step 2. IgA deficiency: go to step 2.
Normal results: in case of recurrent meningococcal infection go to step 2b; in case of recurrent ENT and airway infection wait for 3-6 months to see if clinical condition resolves; if problems persist: go to step 2 (a+b)
Step 2a Antibody deficiency
If not secondary to drugs, lymphoid malignancy, immunoglobulin loss (urine, faeces): booster responses (tetanus; unconjugated pneumococcal vaccine if > 2-3 years of age; a rise in titre appropriate for age to above a defined level should be considered a positive response). Consider IgG-subclasses and M-proteins
Next step Go to step 3.
Step 2b Complement deficiency
Perform CH 50 and AP 50 . Consider MBL. In case of angioedema: C1-inhibitor (level), C4 during attack
Next step Go to step 3
Step 3
Continue with Possible diagnosis

Agammaglobulinaemia (step 1)
Lymphocyte subpopulations (Table 3) , consider lymphocyte proliferation tests (Table 3) , genetic determination of defect if possible X-linked or autosomal recessive form of congenital agamma globulinaemia
Normal results in step 2a
Wait and see. If problems persist repeat total IgG, IgA, IgM, and IgG-subclasses after 1-2 years (6 months if < 1 year of age), and booster responses after 3-5 years. Consider Protocol 3. Consider lymphocyte subpopulations (Table 3) No immunodeficiency, isolated IgA deficiency, developing CVID. TLRsignalling deficiency (IRAK4) (not associated with antibody deficiency)
Abnormal results in step 2a:
IgA and/or IgG2 deficiency Abnormal booster responses Hypogammaglobulinaemia
Consider lymphocyte subpopulations (Table 3) , genetic determination of defect if possible. Consider lymphocyte proliferation tests (Table 3) , chromosomal analysis, CD40, CD40L after stimulation, α-fetoprotein Step 2 Identify the different forms of (severe) combined immunodeficiency
Perform
Lymphocyte proliferation tests (Table 3) Consider lymphocyte subpopulations using a more extended protocol than the one mentioned in Table 3 Grey shading: collaboration with an immunologist or hematologist is highly recommended for this step. ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic autoantibodies; C, complement component; CD, cluster of differentiation; CGD, chronic granulomatous disease; CVID, common variable immunodeficiency; FMF, familial Mediterranean fever; G-CSF, granulocyte-colony-stimulating factor; G6PD, glucose-6-phosphate dehydrogenase; MPO, myeloperoxidase; NADPH, nicotinamide adenine dinucleotide phosphate; PFAPA, periodic fever-aphthous stomatitispharyngitis-cervical adenopathy; RF, rheumatoid factor; SBDS, Schwachman-Bodian-Diamond syndrome; SGD, neutrophil-specific granule deficiency; sLeX, sialyl Lewis X; TLR, Toll-like receptor.
Protocol 3
Step 1 Identify neutropenia Possible diagnosis
Perform
Blood count and differential (absolute neutrophil count, microscopic evaluation); perform repeatedly in case of cyclic pattern of fever and infections (no evidence-based guidelines exist; 3 × /week for 3-6 weeks is advocated in several reviews)
Cyclic neutropenia, Chediak-Higashi syndrome (giant granules), specific granule deficiency (bilobed nuclei), asplenia (HowellJolly bodies)
Next step
Neutropenia: go to step 2. Normal results: determine IgG, IgA, and IgM, CH 50 ; go to step 3. Neutrophilia: go to step 3
Step Haematological malignancy, aplastic anaemia
Step 3 Identify defects in phagocyte function
Possible diagnosis
Perform
Phagocyte function tests (Table 4) . Serum IgE. Consider hair evaluation, consider CD11/18 and sLeX expression (flowcytometry, in case of neutrophilia) Table 3 . Basic protocol for in vitro determination of lymphocyte subpopulations and function. Mitogens (e.g. PHA, PMA + ionomycin, PWM) Consider monoclonal antibodies (e.g. CD2 ± CD28, CD3 ± CD28) Antigens (e.g. tetanus, after booster vaccination) Consider allogeneic cells (a) Can be performed in many hospitals; for correct interpretation of the results, the advice of an immunologist is highly recommended. (b) Collaboration with an immunologist and specialized laboratory is recommended.
Abbreviations: CD = cluster of differentiation, CFSE = carboxyfluorescein succinimidyl ester, HLA = human leucocyte antigen, NK = natural killer, PHA = phytohaemagglutinin, PMA = phorbol myristate acetate, PWM = pokeweed mitogen, TCR = T-cell receptor. 
